One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day.
Leprosy is a chronic skin and peripheral nerve disease, with a clinical spectrum related to the immunity of the patient. Acute inflammatory episodes, called 'reactions', can occur before diagnosis, as well as during or after the end of treatment. Thirty to fifty percent of patients develop this reaction, subdivided into type I reaction, or reverse reaction, and type II reaction, or erythema nodosum leprosum (ENL). 1 The type II reaction is typical of the Virchowian (lepromatous leprosy) pole. The skin presents erythematous and painful nodules throughout the body (ENL), with systemic symptoms. Light cases of the disease can be treated with analgesics and non-steroid anti-inflammatory drugs, whereas in moderate to severe cases, the treatment of choice is thalidomide and corticosteroids. However, these drugs bring about important side effects, and effective alternative schemes would be useful in many cases. The type II leprosy reaction, mediated by immunocomplexes, increases the pro-inflammatory cytokines (tumor necrosis factor alpha -TNF-alpha -and interferon gamma -IFN-gamma), inducing cytotoxic activity and bacillary destruction, followed by the intensification of cytokine secretion, which activates the immune response. In this case report, though there was a good response to etanercept, the reaction is currently only controlled with the administration of the drug in weekly doses. Thalidomide was interrupted, but the attempt to suspend prednisone was followed by a significant reactional outbreak.
Another important point to be considered, in Brazil, is the high risk of the reactivation of latent tuberculosis when using anti-TNF drugs (greater with infliximab when compared to etanercept). The removal of thalidomide and the maintenance of prednisone in low doses shows that the biological agents can be useful in patients with type II leprosy, which is difficult to control, and are capable of reducing the need for thalidomide and prednisone, thus sparing patients of the side effects from both drugs. Therefore, studies conducted with a greater number of patients and longer follow-ups, in an attempt to evaluate and define the risks and benefits of these new drugs, are warranted. q
